Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.32 |
| ▸ | RXRB | P28702 | 3/20 | 0.32 |
| ▸ | RXRG | P48443 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 2/20 | 0.30 |
| ▸ | RARG | P13631 | 2/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644643 | 0.75 | ROCK2 (0.38) | ROCK2ROCK1 | |
| SCHEMBL16703224 | 0.71 | HCAR2 (0.50) | HCAR2RXRARXRBRXRGRARB | |
| SCHEMBL23146241 | 0.68 | HCAR2 (0.47) | HCAR2RXRARXRBRXRGRARB | |
| SCHEMBL2406553 | 0.67 | HCAR2 (0.46) | HCAR2RXRARXRBRXRGRARB | |
| SCHEMBL16794314 | 0.66 | SMN1; SMN2 (0.43) | HCAR2 | |
| SCHEMBL787918 | 0.65 | CHRM2 (0.39) | ROCK2ROCK1PARP1 | |
| SCHEMBL11300941 | 0.65 | KDM4C (0.39) | PARP1 | |
| SCHEMBL30908520 | 0.65 | HCAR2 (0.43) | HCAR2RXRARXRBRXRGRARB | |
| SCHEMBL12900542 | 0.64 | BAZ2A (0.38) | ROCK2ROCK1PARP1SLC6A3KCNH2 | |
| SCHEMBL7526250 | 0.64 | KDM4E (0.44) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846682-B2 | Compound suitable for the treatment of synucleopathies | NEUROPORE THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130035342-A1 | Compound Suitable for the Treatment of Synucleopathies | NEUROPORE THERAPIES, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2513090-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | Neuropore Therapies, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011084642-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035342-A1 | Compound Suitable for the Treatment of Synucleopathies | SNCA, HTT, SMN1; SMN2 | HCAR2 2356/4885ROCK2 2292/4885ROCK1 1901/4885 |
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | SNCA, HTT, MAPT | HCAR2 3837/4885ROCK2 2159/4885ROCK1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.